Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Acquired by Angeles Investment Advisors LLC

Angeles Investment Advisors LLC lifted its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 341.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 18,597 shares of the company’s stock after acquiring an additional 14,381 shares during the quarter. Angeles Investment Advisors LLC’s holdings in Dr. Reddy’s Laboratories were worth $294,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in RDY. EverSource Wealth Advisors LLC boosted its holdings in Dr. Reddy’s Laboratories by 423.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company’s stock valued at $29,000 after purchasing an additional 1,507 shares during the last quarter. POM Investment Strategies LLC lifted its holdings in shares of Dr. Reddy’s Laboratories by 400.0% in the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock valued at $36,000 after buying an additional 1,820 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Dr. Reddy’s Laboratories by 461.0% in the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company’s stock worth $40,000 after buying an additional 2,093 shares during the last quarter. Allworth Financial LP grew its holdings in Dr. Reddy’s Laboratories by 447.8% during the fourth quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock worth $41,000 after acquiring an additional 2,230 shares during the period. Finally, Sierra Ocean LLC purchased a new position in Dr. Reddy’s Laboratories during the fourth quarter valued at approximately $43,000. Institutional investors and hedge funds own 3.85% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on RDY shares. Nomura lowered Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th.

Dr. Reddy’s Laboratories Price Performance

NYSE:RDY opened at $13.73 on Monday. The stock has a market capitalization of $11.46 billion, a PE ratio of 21.86 and a beta of 0.48. Dr. Reddy’s Laboratories Limited has a 52 week low of $12.50 and a 52 week high of $16.89. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The stock’s 50-day moving average price is $13.66 and its 200-day moving average price is $14.68.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, equities analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.